Loss of P16 Protein Expression and Its Association with Epstein‐Barr Virus LMP‐1 Expression in Hodgkin's Lymphoma

Fawzi  Irshaid; Khaled Tarawneh; Aisha Alshdefat; Fatiha Dilmi; Adnan Jaran; Raji Al‐Hadithi; Ahad Al‐Khatib

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

Outlines

Abstract
Copyright

Loss of P16 Protein Expression and Its Association with Epstein‐Barr Virus LMP‐1 Expression in Hodgkin's Lymphoma

Author(s):

Fawzi Irshaid^1,*,

Khaled Tarawneh²,

Aisha Alshdefat³,

Fatiha Dilmi¹,

Adnan Jaran¹,

Raji Al‐Hadithi⁴,

Ahad Al‐Khatib⁴

1Dept. of Biological Sciences, Faculty of Science, Al al-Bayt University, Al-Mafraq, Jordan

2Dept. of Biological Sciences, Faculty of Science, Mutah University, Mutah, Jordan

3Mafraq Hospital of Children and Maternity, Al-Mafraq, Jordan

4Dept. of Pathology, Faculty of Medicine, Jordan University of Sciences and Technology, Irbid, Jordan

International Journal of Cancer Management:Vol. 6, issue 2; e80404

Published online:Jun 30, 2013

Article type:Research Article

Received:Jan 29, 2013

Accepted:Feb 23, 2013

How to Cite:Fawzi IrshaidKhaled TarawnehAisha AlshdefatFatiha DilmiAdnan JaranRaji Al‐HadithiAhad Al‐Khatibet al.Loss of P16 Protein Expression and Its Association with Epstein‐Barr Virus LMP‐1 Expression in Hodgkin's Lymphoma.Int J Cancer Manag.6(2):e80404.

Abstract

Background: Expression of Epstein-Barr virus Latent Member Protein-1 (EBV LMP1) and loss of P16 protein expression are documented in lymphoma, indicating a relationship between them, but this relationship is not clear and sometimes contradictory. Thus, this study was conducted to examine the relationship between the loss of P16 and EBV LMP-1 expression in Jordanian patients diagnosed with lymphoma.

Methods: Sections were made from archival formalin-fixed and paraffinembedded blocks from 55 patients diagnosed with lymphoma. P16 expression and LMP-1 expression were detected by immunohistochemistry using monoclonal antibodies.

Results: In Hodgkin's Lymphoma (HL), the loss of P16 was higher in LMP-1 positive cases (61%) than LMP-1 negative cases (25%; P = 0.072). Conversely, in NonHodgkin's Lymphoma (NHL), none of LMP-1 positive samples showed loss of P16. Furthermore, among LMP-1 HL positive cases, the loss of P16 was more frequent in male (75%) than female (33%). Also, there was a significantly higher proportion of LMP-1 positive cases showing loss of P16 in HL (11:18), compared to those in NHL (0:8, P < 0.001), confirming a difference between HL and NHL, concerning the LMP-1/P16 relationship.

Conclusion: A trend for an association between loss of P16 and LMP-1 expression was observed in HL but not NHL patients. These findings suggest that there are molecular and clinical differences in the pathogenesis and development of different subtypes of lymphoma.

Keywords

Epstein-Barr virus infections

Immunohistochemistry

Lymphoma

Monoclonal antibodies

Fulltext

The Full text is available in PDF.

comments